

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

**Listing of Claims:**

1-10. (Previously Cancelled)

11. (Previously Withdrawn) A process of marking a receptor comprising the steps of a) radiolabelling a compound as defined in claim 1; b) administering said radiolabelled compound to biological material, c) detecting the emissions from the radiolabelled compound.


12. (Previously Withdrawn) A process of imaging an organ, characterized by, administering a sufficient amount of a radiolabelled compound of formula (I) in an appropriate composition, and detecting the emissions from the radioactive compound.

13. (Previously Cancelled)

14. (Previously Cancelled)

15-22. (Previously Cancelled)

23. A compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, or 2;

q represents an integer being 0, 1, or 2;

X represents O, S, NR<sup>3</sup> or a direct bond;

R<sup>1</sup> represents hydrogen, hydroxy, halo, amino, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy or mono- or di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylamino; in particular, hydrogen, methyl and hydroxy;

R<sup>2</sup> represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>;

each R<sup>4</sup> independently represents C<sub>1-6</sub>alkyl, halo, polyhaloC<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyloxy;

each R<sup>5</sup> independently represents C<sub>1-6</sub>alkyl, halo or C<sub>1-6</sub>alkyloxy;

each R<sup>6</sup> independently represents C<sub>1-6</sub>alkylsulfonyl, aminosulfonyl or phenylC<sub>1-4</sub>alkylsulfonyl;

each R<sup>7</sup> and each R<sup>8</sup> are independently selected from hydrogen, C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl, dihydroxyC<sub>1-4</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, mono- or di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, arylaminocarbonyl, arylaminothiocarbonyl, C<sub>3-7</sub>cycloalkyl, pyridinylC<sub>1-4</sub>alkyl, Het<sup>3</sup> and R<sup>6</sup>;

R<sup>9</sup> and R<sup>10</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkylcarbonyl, hydroxyC<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkylcarbonyl, Het<sup>3</sup>aminothiocarbonyl and R<sup>6</sup>;

each R<sup>11</sup> independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C<sub>1-4</sub>alkyloxy, carboxyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkylcarbonyl, trihaloC<sub>1-4</sub>alkylsulfonyloxy, R<sup>6</sup>, NR<sup>7</sup>R<sup>8</sup>, C(=O)NR<sup>7</sup>R<sup>8</sup>, aryl, aryloxy, arylcarbonyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkyloxy, phthalimide-2-yl, Het<sup>3</sup> and C(=O)Het<sup>3</sup>;

R<sup>12</sup> and R<sup>13</sup> are each independently selected from hydrogen and C<sub>1-4</sub>alkyl;

aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, halo, hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, polyhaloC<sub>1-4</sub>alkyl, NR<sup>9</sup>R<sup>10</sup>, R<sup>6</sup>, phenyl, Het<sup>3</sup> and C<sub>1-4</sub>alkyl substituted with NR<sup>9</sup>R<sup>10</sup>;

Het<sup>1</sup> represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl, furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl, 1*H*-pyrazolo-[3,4-*d*]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl, imidazo-[2,1-*b*]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>;

Het<sup>2</sup> represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with C<sub>1-4</sub>alkyl;

Het<sup>3</sup> represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two or three substituents each independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyl, phenylC<sub>1-4</sub>alkyl, piperidinyl, NR<sup>12</sup>R<sup>13</sup> and C<sub>1-4</sub>alkyl substituted with NR<sup>12</sup>R<sup>13</sup>.

24. A compound according to claim 23 wherein the 6-azauracil moiety is in the para position relative to the central carbon atom.

25. A compound according to claim 24 wherein q is 1 or 2 and one R<sup>4</sup> substituent is in the 4 position; and p is 1 or 2 and the one or two R<sup>5</sup> substituents are in the ortho position relative to the central carbon atom.

26. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 23.

27. A process for preparing a composition as claimed in claim 26, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in claim 23.

28. **(Currently Cancelled)**

29. **(Currently Amended)** A method for treating one or more of: eosinophil-dependent inflammatory diseases bronchial asthma, atopic dermatitis, allergic-rhinitis or allergic conjunctivitis in a warm-blooded animal in need thereof comprising administering to the warm-blooded animal an effective amount of a compound of Claim 23.

30. **(Currently Cancelled).**

31. (New) A method for inhibiting IL-5 production in a warm-blooded animal, comprising administering to the warm-blooded animal an effective amount of a compound of claim 23.